<img height="1" width="1" src="https://www.facebook.com/tr?id=914352225269004&amp;ev=PageView &amp;noscript=1">
HubSpot Video
New Common Cold Clinical Trial

Hate getting colds every year?

Help researchers learn more about a new potential treatment for the common cold.
Qualify to take part and you may receive reimbursement whilst helping advance medical science

Click here or scroll down to learn about this study's inclusion criteria ⬇️

By signing up to Evrima Connect, you consent to Evrima Technologies' Terms of Service and Privacy Policy.

If you take part in the research study you will receive:

Reimbursement of costs

For out-of-pocket expenses, such as travel and parking.

Free study-related medical care

You may gain access to new potential treatments, before they are widely available.

No overnight stays or blood samples!

All study visits are out-patient only. No blood samples will be needed

Do your part to help advance breakthroughs in medical research

🏥 Study Guide

Who can take part in this study?

In order to be eligible to participate in the study, you must meet all of the following:

  • You are aged 18 years or older
  • You believe you have a cold
  • Your symptoms have started in the 24 hours prior to commencing the study

Why should you register if you don’t have a cold?

We are looking to enrol participants within the first 24 hours of experiencing cold symptoms. If you register early, we will remind you about this study and you can contact us straight away when symptoms develop via email (commoncoldstudy@evrima.com.au). 

Who is unable to take part in this study?

Unfortunately, if you meet any of the following, this study is not the right fit for you:

  • You are currently positive for COVID-19
  • You were recently vaccinated at the time you start the study
  • You are pregnant, planning pregnancy or breast-feeding
  • You have a thyroid condition or undergoing thyroid treatment
  • You are allergic to iodine

How long will the study take?

If you agree to take part, and the study is suitable for you, your participation in the study will be 14 days. This includes:

  • One initial visit to the trial site for enrolment
  • Treatment for 5 days (at home or work)
  • Daily reporting in a webapp diary for a total of 14 days
  • A PCR test to exclude COVID-19 infection

What is the purpose of this study?

This study aims to test a new nasal spray that kills viruses in the nose and may be a valuable new treatment for the common cold. It has already been tested in several trials and shown to be safe.

What is the common cold?

Colds are minor infections of the nose caused by more than 200 different viruses. Cold-causing viruses can be found in all corners of the world. Rhinovirus is the most common cause, accounting for around 50% of colds. Sore throat and runny nose are usually the first signs of a cold, followed by tiredness, body aches and pains, congestion, coughing and sneezing. 

Colds are most often spread through airborne respiratory droplets, but can also come from touching contaminated surfaces, and skin-to-skin contact (such as shaking hands). Adults get an average of 2-4 colds per year, mostly during the winter months, while young children suffer from an average of 6-8 colds per year.

Where is my nearest study site?

Here is a list of all of the sites who are currently recruiting for this study:

  • SA, Adelaide, Norwood - CMAX/Fusion Clinical Research
  • VIC, Belmont - Kardinia Health
  • VIC, Ballarat - UFS Dispensaries


What if I have other questions about the study?

We are here for you! Click or tap this button to send an email to our Patient Experience team: